# Caroline A Sabin

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/82901/caroline-a-sabin-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

601 34,652 167 92 h-index g-index citations papers 38,619 6.59 640 6.5 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
601	Association between health-related quality of life and menopausal status and symptoms in women living with HIV aged 45-60 years in England: An analysis of the PRIME study <i>Womends Health</i> , <b>2022</b> , 18, 17455065211068722	3	1
600	Genetic Variants of Are Major Determinants of Kidney Failure in People of African Ancestry With HIV <i>Kidney International Reports</i> , <b>2022</b> , 7, 786-796	4.1	1
599	Comorbidities in women living with HIV: A systematic review HIV Medicine, 2022, 23, 331-361	2.7	0
598	Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK <i>HIV Medicine</i> , <b>2022</b> , 23, 390-396	2.7	
597	Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV <i>Kidney International Reports</i> , <b>2022</b> , 7, 465-473	4.1	O
596	Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e747-e754	7.8	1
595	Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> ,	5.1	1
594	Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 33, 129	96- <del>1</del> 1307	,
593	Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa561	1	7
592	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , <b>2021</b>	11.6	84
591	SPECIAL ISSUE HIV and CHRONIC PAIN (The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, <b>2021</b> , 1-9	2.2	2
590	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2021</b> , 86, 579-586	3.1	2
589	The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London. <i>HIV Medicine</i> , <b>2021</b> , 22, 641-649	2.7	1
588	Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity. <i>Aids</i> , <b>2021</b> , 35, 1813-1821	3.5	1
587	Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. <i>HIV Medicine</i> , <b>2021</b> , 22, 631-640	2.7	1
586	No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100lcells/lll. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25726	5.4	2
585	Menopausal status, age and management among women living with HIV in the UK. <i>HIV Medicine</i> , <b>2021</b> , 22, 834-842	2.7	1

# (2020-2021)

584	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , <b>2021</b> , 12, 4450	17.4	10
583	Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253861	3.7	O
582	The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 33, 101-108	2.2	11
581	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 632-637	7	1
580	Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors. <i>HIV Medicine</i> , <b>2021</b> , 22, 47-53	2.7	2
579	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. <i>Sexually Transmitted Infections</i> , <b>2021</b> , 97, 177-182	2.8	1
578	Respiratory symptoms and chronic bronchitis in people with and without HIV infection. <i>HIV Medicine</i> , <b>2021</b> , 22, 11-21	2.7	3
577	"I have failed to separate my HIV from this pain": the challenge of managing chronic pain among people with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 1-9	2.2	1
576	Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. <i>Sleep</i> , <b>2021</b> , 44,	1.1	1
575	Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 1-10	2.2	1
574	Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: results from the PRIME Study. <i>Sexually Transmitted Infections</i> , <b>2021</b> ,	2.8	5
573	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25690	5.4	1
572	Cardiovascular risks associated with protease inhibitors for the treatment of HIV. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 1351-1366	4.1	2
571	The epidemiology of kidney disease in people of African ancestry with HIV in the UK. <i>EClinicalMedicine</i> , <b>2021</b> , 38, 101006	11.3	3
570	COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England. <i>HIV Medicine</i> , <b>2021</b> ,	2.7	1
569	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , <b>2021</b> , 1	3.9	O
568	Associations of menopausal age with virological outcomes and engagement in care among women living with HIV in the UK. <i>HIV Research and Clinical Practice</i> , <b>2020</b> , 21, 174-181	1.7	О
567	Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. <i>HIV Medicine</i> , <b>2020</b> , 21, 441-452	2.7	2

566	Monitoring of older HIV-1-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. <i>HIV Medicine</i> , <b>2020</b> , 21, 409-417	2.7	1
565	High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1575-1579	5.1	8
564	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , <b>2020</b> , 21, 309-321	2.7	1
563	Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 677-688	5.5	4
562	Late diagnosis of human immunodeficiency virus infection is linked to higher rates of epilepsy in children in the Eastern Cape of South Africa. <i>Southern African Journal of HIV Medicine</i> , <b>2020</b> , 21, 1047	1.4	Ο
561	CD4:CD8 T-cell ratio changes in people with HIV receiving antiretroviral treatment. <i>Antiviral Therapy</i> , <b>2020</b> , 25, 91-100	1.6	1
560	Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIV. <i>International Journal of STD and AIDS</i> , <b>2020</b> , 31, 30-37	1.4	0
559	Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. <i>Aids</i> , <b>2020</b> , 34, 1813-1821	3.5	2
558	Associations Between Widespread Pain and Sleep Quality in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 85, 106-112	3.1	9
557	HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 101, 374-379	10.5	2
556	CD4+:CD8+ T Cell Ratio Normalization and the Development of AIDS Events in People with HIV Starting Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 808-816	1.6	3
555	Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 581616	8.4	3
554	The predictors of pain extent in people living with HIV. Aids, 2020, 34, 2071-2079	3.5	3
553	First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. <i>Aids</i> , <b>2020</b> , 34, 1823-1831	3.5	3
552	Do people living with HIV experience greater age advancement than their HIV-negative counterparts?. <i>Aids</i> , <b>2019</b> , 33, 259-268	3.5	56
551	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EClinicalMedicine</i> , <b>2019</b> , 13, 91-100	11.3	7
550	HIV coinfection among persons diagnosed with hepatitis B in England in 2008-2014. <i>HIV Medicine</i> , <b>2019</b> , 20, 255-263	2.7	4
549	Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 193-201	1.6	20

548	Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above. <i>AIDS Research and Human Retroviruses</i> , <b>2019</b> , 35, 453-460	1.6	5	
547	PRIME (Positive Transitions Through the Menopause) Study: a protocol for a mixed-methods study investigating the impact of the menopause on the health and well-being of women living with HIV in England. <i>BMJ Open</i> , <b>2019</b> , 9, e025497	3	12	
546	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , <b>2019</b> , 188, 1569-1577	3.8	45	
545	Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213440	3.7	4	
544	Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. <i>International Journal of STD and AIDS</i> , <b>2019</b> , 30, 440-446	1.4	6	
543	Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. <i>HIV Medicine</i> , <b>2019</b> , 20, 347-352	2.7	9	
542	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , <b>2019</b> , 38, 2428-2446	2.3	10	
541	Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. <i>HIV Medicine</i> , <b>2019</b> , 20, 274-285	2.7	14	
540	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 650-657	11.6	14	
539	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1629-1634	7	5	
538	Protocol of a two arm randomised, multi-centre, 12-month controlled trial: evaluating the impact of a Cognitive Behavioural Therapy (CBT)-based intervention Supporting UPtake and Adherence to antiretrovirals (SUPA) in adults with HIV. <i>BMC Public Health</i> , <b>2019</b> , 19, 905	4.1	1	
537	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 204-211	2.8	3	
536	Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. <i>Aids</i> , <b>2019</b> , 33, 1871-1880	3.5	13	
535	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , <b>2019</b> , 33, 2173-2188	3.5	5	
534	Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 562-571	3.1	15	
533	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 314-320	3.1	4	
532	High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. <i>HIV Medicine</i> , <b>2019</b> , 20, 131-136	2.7	5	
531	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. <i>Clinical Infectious Diseases</i> , 2019, 69, 1136-1143	11.6	5	

530	No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1899-1909	11.6	58
529	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25083	5.4	7
528	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 893-903	11.6	75
527	Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 482-490	3.4	20
526	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 598-607	9.7	7
525	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e291-e300	7.8	105
524	Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data. <i>AIDS Research and Therapy</i> , <b>2018</b> , 15, 11	3	3
523	Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , <b>2018</b> , 32, 79-88	3.5	12
522	PatientsNperspectives on the development of HIV services to accommodate ageing with HIV: a qualitative study. <i>International Journal of STD and AIDS</i> , <b>2018</b> , 29, 483-490	1.4	5
521	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, 199-2	20 <sup>3</sup> 5 <sup>1</sup>	5
520	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, 102-109	3.1	2
519	Prevalence of diagnosed HIV infection among persons with hepatitis C virus infection: England, 2008-2014. <i>HIV Medicine</i> , <b>2018</b> , 19, 708-715	2.7	6
518	A qualitative assessment of the acceptability of hepatitis C remote self-testing and self-sampling amongst people who use drugs in London, UK. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 281	4	13
517	Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194760	3.7	25
516	Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>HIV Medicine</i> , <b>2018</b> , 19, 605-618	2.7	13
515	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1767-1772	7	9
514	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e301-e308	7.8	23
513	The association between detected drug resistance mutations and CD4 T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 105-116	1.6	1

# (2017-2018)

512	The NCOmorBidity in Relation to AIDSN(COBRA) cohort: Design, methods and participant characteristics. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191791	3.7	7
511	Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls. <i>Aids</i> , <b>2018</b> , 32, 2077-2081	3.5	4
510	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , <b>2018</b> , 32, 327-335	3.5	11
509	Cardiovascular disease in women living with HIV: A narrative review. <i>Maturitas</i> , <b>2018</b> , 108, 58-70	5	13
508	HIV I the good news. <i>Trends in Urology &amp; Mend Health</i> , <b>2018</b> , 9, 21-24	0.3	
507	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , <b>2018</b> , 32, 2697-2706	3.5	30
506	Patterns of Co-occurring Comorbidities in People Living With HIV. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy272	1	26
505	Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, 206-225	3.1	11
504	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2018</b> , 78, 579-588	3.1	18
503	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 1391-1392e	7.8	27
502	Associations between serum albumin and serious non-AIDS events among people living with HIV. <i>Aids</i> , <b>2018</b> , 32, 1837-1848	3.5	3
501	Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , <b>2017</b> , 45, 215-220	5.8	7
500	Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. <i>Journal of Infection</i> , <b>2017</b> , 74, 492-500	18.9	33
499	Increased brain-predicted aging in treated HIV disease. <i>Neurology</i> , <b>2017</b> , 88, 1349-1357	6.5	133
498	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e251-e259	7.8	9
497	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , <b>2017</b> , 31, 1261-1270	3.5	15
496	Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients. <i>Aids</i> , <b>2017</b> , 31, 643-652	3.5	22
495	An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. Journal of Antimicrobial Chemotherapy, <b>2017</b> , 72, 2075-2082	5.1	6

494	A discrete choice experiment to assess people living with HIVN (PLWHIVN) preferences for GP or HIV clinic appointments. <i>Sexually Transmitted Infections</i> , <b>2017</b> , 93, 105-111	2.8	12
493	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e295-e302	7.8	38
492	A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. <i>HIV Medicine</i> , <b>2017</b> , 18, 655-666	2.7	2
491	Epidemiology of ageing with HIV: what can we learn from cohorts?. <i>Aids</i> , <b>2017</b> , 31 Suppl 2, S121-S128	3.5	40
490	Association between engagement in-care and mortality in HIV-positive persons. <i>Aids</i> , <b>2017</b> , 31, 653-660	3.5	18
489	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1644-1656	11.6	42
488	Gray and White Matter Abnormalities in Treated Human Immunodeficiency Virus Disease and Their Relationship to Cognitive Function. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 422-432	11.6	47
487	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183357	3.7	27
486	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002424	11.6	12
485	Benchmarked performance charts using principal components analysis to improve the effectiveness of feedback for audit data in HIV care. <i>BMC Health Services Research</i> , <b>2017</b> , 17, 506	2.9	1
484	High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx108	1	12
483	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 217, 69-81	7	32
482	Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. <i>British Journal of Surgery</i> , <b>2017</b> , 104, 1539-1548	5.3	53
481	Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. <i>Aids</i> , <b>2017</b> , 31, 2525-2532	3.5	45
480	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 311-318	3.1	8
479	Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. <i>Aids</i> , <b>2017</b> , 31, 485-492	3.5	22
478	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , <b>2017</b> , 18, 171-180	2.7	33
477	Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV. <i>HIV Medicine</i> , <b>2017</b> , 18, 363-369	2.7	20

# (2016-2017)

476	Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. <i>HIV Medicine</i> , <b>2017</b> , 18, 204-213	2.7	53
475	Development and application of a new measure of engagement in out-patient HIV care. <i>HIV Medicine</i> , <b>2017</b> , 18, 267-274	2.7	14
474	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-name patients. <i>HIV Medicine</i> , <b>2017</b> , 18, 33-44	2.7	10
473	Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, 21577	5.4	26
472	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173893	3.7	23
471	REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. <i>Health Services and Delivery Research</i> , <b>2017</b> , 5, 1-160	1.5	8
470	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 214-23	3.9	127
469	The menopause transition in women living with HIV: current evidence and future avenues of research. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 114-116	2.8	13
468	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , <b>2016</b> , 17 Suppl 4, s2-s104	2.7	63
467	No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1302-1308	7	8
466	Understanding HIV-positive patients Noreferences for healthcare services: a protocol for a discrete choice experiment. <i>BMJ Open</i> , <b>2016</b> , 6, e008549	3	3
465	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 654	4	6
464	Defining cognitive impairment in people-living-with-HIV: the POPPY study. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 617	4	45
463	Which aspects of health care are most valued by people living with HIV in high-income countries? A systematic review. <i>BMC Health Services Research</i> , <b>2016</b> , 16, 677	2.9	16
462	How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?. <i>Current Opinion in HIV and AIDS</i> , <b>2016</b> , 11, 487-491	4.2	9
461	Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 495-506	1.6	15
460	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5133	1.8	2
459	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , <b>2016</b> , 14, 61	11.4	84

458	Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. <i>HIV Medicine</i> , <b>2016</b> , 17, 255-68	2.7	88
457	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 565-575	25.5	175
456	Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 2099-2107	4.3	46
455	Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , <b>2016</b> , 17, 368-72	2.7	5
454	Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates. <i>HIV Medicine</i> , <b>2016</b> , 17, 28-35	2.7	13
453	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1352-60	5.1	3
452	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 2038-2049	7.8	24
451	The menopause transition in women living with HIV: current evidence and future avenues of research. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 114-6	2.8	4
450	HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 3487-3494	5.1	20
449	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. <i>Aids</i> , <b>2016</b> , 30, 1731-43	3.5	42
448	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. Aids, 2016, 30, 1629-	- <b>3</b> ,7 <sub>5</sub>	8
447	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , <b>2016</b> , 30, 1583-96	3.5	8
446	Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 100-8	3.1	13
445	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> ,	3.1	11
444	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw009	1	16
443	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1072-1080	11.6	106
442	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1212-20	7	28
441	Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , <b>2015</b> , 66, 33-7	14.5	23

## (2014-2015)

440	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV,the</i> , <b>2015</b> , 2, e335-43	7.8	41
439	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , <b>2015</b> , 29, 193-200	3.5	9
438	Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 68, 568-77	3.1	31
437	Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. <i>European Journal of Surgical Oncology</i> , <b>2015</b> , 41, 1500-7	3.6	26
436	Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study. <i>HIV Medicine</i> , <b>2015</b> , 16, 219-29	2.7	8
435	Renal tubular disease in the era of combination antiretroviral therapy. <i>Aids</i> , <b>2015</b> , 29, 1831-6	3.5	21
434	Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. <i>Aids</i> , <b>2015</b> , 29, 801-9	3.5	6
433	Use of surveillance data on HIV diagnoses with HIV-related symptoms to estimate the number of people living with undiagnosed HIV in need of antiretroviral therapy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0121992	3.7	8
432	Clinical and epidemiological characteristics of patients with early syphilis from three academic centres in Poland, Germany and Ireland: initial findings from the POETS study. <i>Sexually Transmitted Infections</i> , <b>2015</b> , 91, 389-94	2.8	2
431	The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. <i>Aids</i> , <b>2015</b> , 29, 2269-78	3.5	21
430	Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1682-1685.6	1 <sup>1.5</sup>	9
429	Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1262-8	11.6	5
428	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , <b>2015</b> , 20,	19.8	55
427	Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients. <i>Clinical Journal of Pain</i> , <b>2015</b> , 31, 813-819	3.5	23
426	The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. <i>Journal of Infection</i> , <b>2014</b> , 68, 77-84	18.9	24
425	Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. <i>Journal of the American College of Surgeons</i> , <b>2014</b> , 218, 401-11	4.4	141
424	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). <i>HIV Medicine</i> , <b>2014</b> , 15 Suppl 1, 1-85	2.7	78
423	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV,the</i> , <b>2014</b> , 1, e41-8	7.8	8

422	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , <b>2014</b> , 384, 241-8	40	622
421	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1312-21	11.6	107
420	Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. <i>HIV Medicine</i> , <b>2014</b> , 15, 595-603	2.7	38
419	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , <b>2014</b> , 15, 51	2.7	6
418	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , <b>2014</b> , 83, 134-41	6.5	85
417	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. <i>Aids</i> , <b>2014</b> , 28, 919-24	3.5	8
416	Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19512	5.4	28
415	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , <b>2014</b> , 2, E318-29	2.5	13
414	The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. <i>HIV Medicine</i> , <b>2014</b> , 15, 311-6	2.7	9
413	Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART nalle women. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 127	4	2
412	Relative contribution of HIV infection, demographics and body mass index to bone mineral density. <i>Aids</i> , <b>2014</b> , 28, 2051-60	3.5	57
411	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. <i>Aids</i> , <b>2014</b> , 28, 1193-202	3.5	341
410	Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. <i>Aids</i> , <b>2014</b> , 28, 1333-9	3.5	9
409	Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 363-73	7	76
408	End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 67, 177-80	3.1	20
407	The Effect of HBV Genotype C on the Development of HCC Differs Between Wild-Type Viruses and Those With BCP Double Mutations (T(1762)A(1764)). <i>Hepatitis Monthly</i> , <b>2014</b> , 14, e16214	1.8	8
406	Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir. <i>AIDS Research and Therapy</i> , <b>2013</b> , 10, 13	3	1
405	Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1659-66	5.6	46

404	Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. <i>Gastroenterology</i> , <b>2013</b> , 144, 751-760.e2	13.3	68
403	Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?. <i>BMC Medicine</i> , <b>2013</b> , 11, 251	11.4	100
402	Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. <i>HIV Medicine</i> , <b>2013</b> , 14, 571-7	2.7	7
401	Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. <i>Aids</i> , <b>2013</b> , 27, 407-15	3.5	84
400	Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. <i>Aids</i> , <b>2013</b> , 27, 95-103	3.5	18
399	The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. <i>Aids</i> , <b>2013</b> , 27, 2245-53	3.5	18
398	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , <b>2013</b> , 27, 2735-48	3.5	44
397	Aspartate aminotransferase-to-platelet ratio index is a powerful predictor of mortality among HIV-positive patients. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 367-8	7	3
396	HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 162-3	11.6	3
395	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , <b>2013</b> , 10, e1001510	11.6	212
394	The natural history of HIV infection. Current Opinion in HIV and AIDS, 2013, 8, 311-7	4.2	37
393	Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 870-9	11.6	38
392	The incidence of AIDS-defining illnesses at a current CD4 count I200 cells/II in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 1038-47	11.6	79
391	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , <b>2013</b> , 68, 207-13	7.3	22
390	How likely is environmental or patient cross-contamination of Chlamydia trachomatis DNA to lead to false positive results in patients attending our clinic?. <i>Sexually Transmitted Infections</i> , <b>2013</b> , 89, 105-7	, 2.8	7
389	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1354-9	5.1	26
388	Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 888-97	11.6	76
387	Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2339-43	5.1	12

386	Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. <i>Aids</i> , <b>2013</b> , 27, 1433-41	3.5	119
385	Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 456-63	3.1	13
384	Natural history of HIV-control since seroconversion. <i>Aids</i> , <b>2013</b> , 27, 2451-60	3.5	28
383	Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. <i>Aids</i> , <b>2013</b> , 27, 1839-46	3.5	35
382	Non-AIDS defining cancers in the D:A:D Studytime trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 471	4	58
381	Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. <i>HIV Medicine</i> , <b>2012</b> , 13, 526-32	2.7	19
380	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , <b>2012</b> , 13 Suppl 2, 1-85	2.7	87
379	Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. <i>American Journal of Kidney Diseases</i> , <b>2012</b> , 60, 539-47	7.4	41
378	Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. <i>BMC Medical Research Methodology</i> , <b>2012</b> , 12, 110	4.7	6
377	Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. <i>BMC Medical Research Methodology</i> , <b>2012</b> , 12, 30	4.7	8
376	Non-uptake of highly active antiretroviral therapy among patients with a CD4 count . <i>HIV Medicine</i> , <b>2012</b> , 13, 73-8	2.7	3
375	British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. <i>HIV Medicine</i> , <b>2012</b> , 13, 1-44	2.7	132
374	Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. <i>BMJ, The</i> , <b>2012</b> , 345, e5253	5.9	38
373	Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 535-9	7	27
372	Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 540-7	7	3
371	Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 408-13	11.6	15
370	Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 1364-72	11.6	53
369	All-cause mortality in treated HIV-infected adults with CD4 B00/mm3 compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , <b>2012</b> , 41, 433-45	7.8	184

# (2011-2012)

368	Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients.  Nephrology Dialysis Transplantation, <b>2012</b> , 27, 2291-7	4.3	57	
36 <del>,</del>	HIV-Infected Late Presenter Patients. AIDS Research and Treatment, <b>2012</b> , 2012, 902679	2.3	6	
360	Biomarkers to monitor safety in people on art and risk of mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 60, 51-8	3.1	14	
36 <u>.</u>	Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. <i>Clinical Investigation</i> , <b>2012</b> , 2, 255-264		10	
364	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , <b>2012</b> , 26, 1707-17	3.5	8	
36 <u>;</u>	Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. <i>PLoS ONE</i> , <b>2012</b> , 7, e49314	3.7	26	
362	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , <b>2012</b> , 26, 1691-705	3.5	28	
36:	Late HIV presentation: epidemiology, clinical implications and management. <i>Expert Review of</i> Anti-Infective Therapy, <b>2011</b> , 9, 877-89	5.5	29	
360	A complex hepatitis B virus (X/C) recombinant is common in Long An county, Guangxi and may have originated in southern China. <i>Journal of General Virology</i> , <b>2011</b> , 92, 402-11	4.9	22	
359	Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. <i>PLoS ONE</i> , <b>2011</b> , 6, e26009	3.7	16	
358	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ, The</i> , <b>2011</b> , 343, d6016	5.9	225	
357	Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 747-53	2.2	15	
356	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , <b>2011</b> , 25, 1497-504	<b>4</b> 3.5	36	
355	CD4 lymphocyte count as predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs. <i>International Journal of Pharmacy Practice</i> , <b>2011</b> , 1, 210-211	1.7	2	
354	Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents. <i>Aids</i> , <b>2011</b> , 25, 1014-5	3.5	2	
353	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. <i>Aids</i> , <b>2011</b> , 25, 1041-9	3.5	13	
352	The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.  Epidemiology, <b>2011</b> , 22, 516-23	3.1	111	
35	High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. <i>Aids</i> , <b>2011</b> , 25, 867-9	3.5	12	

350	The impact of HIV drug resistance testing on changes to treatment. Aids, 2011, 25, 603-10	3.5	8
349	Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 805-14	1.6	29
348	When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 509-15	8	167
347	Risk factors associated with early hepatic artery thrombosis after orthotopic liver transplantation - univariable and multivariable analysis. <i>Transplant International</i> , <b>2011</b> , 24, 401-8	3	68
346	Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 220-20-20 laboratories worldwide using lyophilized plasmas.	2 <sup>15.4</sup>	7
345	Late presentation of HIV infection: a consensus definition. HIV Medicine, 2011, 12, 61-4	2.7	279
344	Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. <i>HIV Medicine</i> , <b>2011</b> , 12, 289-98	2.7	14
343	Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). <i>HIV Medicine</i> , <b>2011</b> , 12, 412-21	2.7	136
342	Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. <i>HIV Medicine</i> , <b>2011</b> , 12, 583-93	2.7	24
341	AuthorsNesponse to Drs Scourfield, Jackson and Nelson. HIV Medicine, <b>2011</b> , 12, 450-451	2.7	
340	HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 527-34	6	67
339	Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. <i>Neurology</i> , <b>2011</b> , 76, 693-700	6.5	38
338	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1886-96	5.1	39
337	Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. <i>Aids</i> , <b>2011</b> , 25, 1647-55	3.5	11
336	Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. <i>PLoS ONE</i> , <b>2011</b> , 6, e25665	3.7	5
335	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2010</b> , 53, 633-639	3.1	23
334	Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 318-30	7	479
333	Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> ,		253

# (2010-2010)

Factors influencing lopinavir and atazanavir plasma concentration. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 129-37	5.1	21
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , <b>2010</b> , 7, 19-35	2.2	30
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapythe CASCADE collaboration: a collaboration of 23 cohort studies. <i>PLoS Medicine</i> , <b>2010</b> , 7, e1000239	11.6	48
Assessment of hospitalizations among HIV patients in the UK: a national cross-sectional survey. <i>International Journal of STD and AIDS</i> , <b>2010</b> , 21, 752-4	1.4	3
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. <i>Aids</i> , <b>2010</b> , 24, 2239-44	3.5	40
Data linkage reduces loss to follow-up in an observational HIV cohort study. <i>Journal of Clinical Epidemiology</i> , <b>2010</b> , 63, 1101-9	5.7	22
Early initiation of treatment for HIV infection. <i>Lancet, The</i> , <b>2010</b> , 375, 639	40	4
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , <b>2010</b> , 376, 340-	5 <sup>40</sup>	77
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 56	9 <i>-</i> 374	33
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , <b>2010</b> , 24, 123-37	3.5	270
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , <b>2010</b> , 24, 427-35	3.5	67
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. <i>Aids</i> , <b>2010</b> , 24, 1739-47	3.5	103
Cohort studies: to what extent can they inform treatment guidelines?. <i>Current Opinion in Infectious Diseases</i> , <b>2010</b> , 23, 15-20	5.4	5
Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. <i>Current Opinion in HIV and AIDS</i> , <b>2010</b> , 5, 473-9	4.2	60
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. <i>Aids</i> , <b>2010</b> , 24, 1537-48	3.5	332
Definition and epidemiology of late presentation in Europe. <i>Antiviral Therapy</i> , <b>2010</b> , 15 Suppl 1, 3-8	1.6	40
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 1077-86	1.6	33
Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC. Journal of the International AIDS Society, <b>2010</b> , 13, O27-O27	5.4	78
	Chemotherapy, 2010, 65, 129-37  Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical Trials, 2010, 7, 19-35  Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy—the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Medicine, 2010, 7, e1000239  Assessment of hospitalizations among HIV patients in the UK: a national cross-sectional survey. International Journal of STD and AIDS, 2010, 21, 752-4  Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. Aids, 2010, 24, 2239-44  Data linkage reduces loss to follow-up in an observational HIV cohort study. Journal of Clinical Epidemiology, 2010, 63, 1101-9  Early initiation of treatment for HIV infection. Lancet, The, 2010, 375, 639  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-110. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 2010, 17, 56  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Aids, 2010, 24, 123-37  High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. Aids, 2010, 24, 427-35  Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. Aids, 2010, 24, 1739-47  Cohort studies: to what extent can they inform treatment guidelines?. Current Opinion in Infectious Diseases, 2010, 23, 15-20  Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Current Opinion in HIV and AIDS, 2010, 5, 473-9  Factors associated with specific causes of death amongst HIV-positive	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35  Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy—the CASCADE collaboration: a collaboration of 23 cohort studies. <i>PLoS Medicine</i> , 2010, 7, e1000239  Assessment of hospitalizations among HIV patients in the UK: a national cross-sectional survey. <i>International Journal of STD and AIDS</i> , 2010, 21, 752-4  Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. <i>Aids</i> , 35  2010, 24, 2239-44  Data linkage reduces loss to follow-up in an observational HIV cohort study. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1101-9  Early initiation of treatment for HIV infection. <i>Lancet</i> , <i>The</i> , 2010, 375, 639  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microl. in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , <i>The</i> , 2010, 376, 340-540  The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK- trends in HCV testing and the impact of HCV on HIV treatment outcomes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 569-77  High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , 2010, 24, 1739-47  Cohort studies: to what extent can they inform treatment guidelines?. <i>Current Opinion in Infectious Disease</i> , 2010, 23, 15-20  Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. <i>Aids</i> , 2010, 24, 1739-47  Cohort studies: to what extent can they inform treatment guidelines?. <i>Current Opinion in Infectious Disease</i> , 2010, 23, 15-20  Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. <i>Aids</i> , 2010, 24, 1739-47  Cohort studies: to what extent can they inform tr

314	Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. <i>HIV Medicine</i> , <b>2010</b> , 11, 152-60	2.7	41
313	British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. <i>HIV Medicine</i> , <b>2010</b> , 11, 1-30	2.7	63
312	Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. <i>HIV Medicine</i> , <b>2010</b> , 11, 432-8	2.7	26
311	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. <i>Aids</i> , <b>2010</b> , 24, 723-7	3.5	59
310	When should antiretroviral therapy be started in HIV-positive persons?. <i>F1000 Medicine Reports</i> , <b>2010</b> , 2, 81		
309	Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1296-305	11.6	118
308	Virological response to initial antiretroviral regimens containing abacavir or tenofovir. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 710-4	7	8
307	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. <i>Aids</i> , <b>2009</b> , 23, 2507-15	3.5	34
306	HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 8-10	7	4
305	Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. <i>Diabetes Care</i> , <b>2009</b> , 32, 474-80	14.6	28
304	Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1138-5	5 <b>1</b> 11.6	90
303	Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). <i>Circulation</i> , <b>2009</b> , 119, 805-11	16.7	79
302	The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. <i>HIV Medicine</i> , <b>2009</b> , 10, 35-43	2.7	22
301	British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from nate. <i>HIV Medicine</i> , <b>2009</b> , 10, 337-42	2.7	15
300	Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. <i>HIV Medicine</i> , <b>2009</b> , 10, 351-5	2.7	14
299	The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 273-80	13.4	45
298	Early antiretroviral therapy: the role of cohorts. Current Opinion in HIV and AIDS, 2009, 4, 200-5	4.2	3
297	Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Aids, 2009, 23, 2517-21	3.5	41

## (2008-2009)

296	Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 52, 357-63	3.1	24	
295	Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?. <i>Current Opinion in Infectious Diseases</i> , <b>2009</b> , 22, 191-7	5.4	22	
294	Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 52, 588-94	3.1	6	
293	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , <b>2009</b> , 23, 1689-99	3.5	53	
292	CD4 counts and the risk of systemic non-HodgkinN lymphoma in individuals with HIV in the UK. <i>Haematologica</i> , <b>2009</b> , 94, 875-80	6.6	62	
291	Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 52, 391-6	3.1	4	
290	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , <b>2009</b> , 23, 1743-53	3.5	175	
289	Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. <i>HIV Medicine</i> , <b>2008</b> , 9, 47-56	2.7	21	
288	An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy. <i>HIV Medicine</i> , <b>2008</b> , 9, 208-13	2.7	4	
287	The incidence of HIV-related disease in a cohort of haemophilic men: natural history and changes since the introduction of pre-AIDS treatment. <i>International Journal of Laboratory Hematology</i> , <b>2008</b> , 15, 241-251		1	
286	The seroepidemiology of HTLV-I amongst genitourinary medicine (GUM) attendees in South East London. <i>Journal of Clinical Virology</i> , <b>2008</b> , 43, 253-4	14.5	3	
285	Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , <b>2008</b> , 34, 1309-15	3.6	33	
284	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. <i>Atherosclerosis</i> , <b>2008</b> , 196, 248-255	3.1	87	
283	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet, The</i> , <b>2008</b> , 371, 1417-26	40	687	
282	Abacavir and increased risk of myocardial infarction [AuthorsNeply. Lancet, The, 2008, 372, 804-805	40	12	
281	Cervical intraepithelial neoplasia treatment in Human Immunodeficiency Virus-positive women. Journal of Obstetrics and Gynaecology, <b>2008</b> , 28, 327-32	1.3	8	
280	Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. <i>Journal of General Virology</i> , <b>2008</b> , 89, 2882-2890	4.9	84	
279	What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 705-13	5.1	18	

278	Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , <b>2008</b> , 31, 1224-9	14.6	374
277	Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 47, 202-5	3.1	13
276	Stability of antiretroviral regimens in patients with viral suppression. <i>Aids</i> , <b>2008</b> , 22, 1039-46	3.5	31
275	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , <b>2008</b> , 22, 2143-53	3.5	180
274	HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2254-62	0.7	86
273	Impact of HIV on host-virus interactions during early hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1558-66	7	84
272	Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1213-4, author reply 1214-5	7	60
271	Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1101	-10 <sup>.6</sup>	52
270	Designing and interpreting HIV noninferiority trials in naive and experienced patients. <i>Aids</i> , <b>2008</b> , 22, 913-21	3.5	34
269	Cardiovascular risk and choice of HIV drug regimen. Future HIV Therapy, 2008, 2, 83-92		1
268	HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. <i>Pediatric Infectious Disease Journal</i> , <b>2008</b> , 27, 457-9	3.4	27
267	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , <b>2008</b> , 22, 2461-9	3.5	49
266	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. <i>Aids</i> , <b>2008</b> , 22, 349-56	3.5	18
265	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , <b>2008</b> , 22, 1463-73	3.5	173
264	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. <i>Aids</i> , <b>2008</b> , 22, 1943-50	3.5	16
263	Conventional cardiovascular risk factors in HIV infection: how conventional are they?. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 214-9	4.2	11
262	O422 Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?. <i>Journal of the International AIDS Society</i> , <b>2008</b> , 11, O44	5.4	2
261	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , <b>2008</b> , 63, 213-21	9.4	144

## (2007-2008)

260	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 959-67	1.6	47
259	Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 675-85	1.6	46
258	Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 675-685	1.6	72
257	Population Trends in the Prevalence and Patterns of Protease Resistance Related to Exposure to Unboosted and Boosted Protease Inhibitors. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 771-777	1.6	8
256	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 959-967	1.6	46
255	Outpatient medical management of missed miscarriage using misoprostol. <i>Journal of Obstetrics and Gynaecology</i> , <b>2007</b> , 27, 283-6	1.3	18
254	Towards a better liver transplant allocation system. <i>Liver Transplantation</i> , <b>2007</b> , 13, 935-6; author reply 937	4.5	7
253	Treatment outcomes amongst previously antiretroviral-nalle HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital. <i>HIV Medicine</i> , <b>2007</b> , 8, 55-63	2.7	3
252	Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. <i>HIV Medicine</i> , <b>2007</b> , 8, 38-45	2.7	37
251	CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. <i>HIV Medicine</i> , <b>2007</b> , 8, 135-41	2.7	33
250	HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. <i>HIV Medicine</i> , <b>2007</b> , 8, 536-46	2.7	33
249	Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. <i>Aids</i> , <b>2007</b> , 21, 983-91	3.5	319
248	Class of antiretroviral drugs and the risk of myocardial infarction. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1723-35	59.2	1179
247	Natural history and outcome in systemic AA amyloidosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 2361-71	59.2	640
246	Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 59, 1013-6	5.1	5
245	Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 692-700		37
244	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. <i>Aids</i> , <b>2007</b> , 21, 1717-21	3.5	64
243	Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation. <i>Transplantation</i> , <b>2007</b> , 84, 605-10	1.8	10

242	Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. <i>Aids</i> , <b>2007</b> , 21, 1423-30	3.5	25
241	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , <b>2007</b> , 21, 1185-97	3.5	218
240	Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46 Suppl 1, S3-8	3.1	231
239	Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. <i>Lancet, The</i> , <b>2007</b> , 370, 1923-8	40	50
238	Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 62-7	3.1	14
237	Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1626-33	4.5	29
236	Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. <i>Sexually Transmitted Diseases</i> , <b>2006</b> , 33, 96-101	2.4	22
235	Providing written information on HIV testing improves patient knowledge but does not affect test uptake. <i>International Journal of STD and AIDS</i> , <b>2006</b> , 17, 185-8	1.4	3
234	Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 1120-	-4	46
233	Medical student attitudes towards HIV. International Journal of STD and AIDS, 2006, 17, 513-6	1.4	5
232	Reply to Boyd and Bothamley and to Franzetti et al. Clinical Infectious Diseases, 2006, 42, 1499-1500	11.6	
232	Reply to Boyd and Bothamley and to Franzetti et al. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 1499-1500  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41	11.6	869
	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.	11.6 40	869
231	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.  Archives of Internal Medicine, 2006, 166, 1632-41  3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models		
231	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41  3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. <i>Lancet, The</i> , <b>2006</b> , 367, 225-32  Analyse transplant outcomes in distinct epochs of follow-up [AuthorsNeply. <i>Lancet, The</i> , <b>2006</b> ,	40	272
231 230 229	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41  3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. <i>Lancet</i> , <i>The</i> , <b>2006</b> , 367, 225-32  Analyse transplant outcomes in distinct epochs of follow-up [AuthorsNeply. <i>Lancet</i> , <i>The</i> , <b>2006</b> , 367, 1816-1817  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet</i> , <i>The</i> , <b>2006</b> , 368, 451-8  Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and	40	272
231 230 229 228	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Archives of Internal Medicine, 2006, 166, 1632-41  3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet, The, 2006, 367, 225-32  Analyse transplant outcomes in distinct epochs of follow-up [AuthorsNeply. Lancet, The, 2006, 367, 1816-1817  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet, The, 2006, 368, 451-8  Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and	40 40 40	272 1 187

224	Changes in AIDS-Defining Illnesses in a London Clinic, 1987???1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>2006</b> , 21, 401		9
223	A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. <i>Aids</i> , <b>2006</b> , 20, 2043-50	3.5	198
222	Cervical screening in HIV-positive women: characteristics of those who default and attitudes towards screening. <i>HIV Medicine</i> , <b>2006</b> , 7, 46-52	2.7	13
221	Determinants of response to first HAART regimen in antiretroviral-nalle patients with an estimated time since HIV seroconversion. <i>HIV Medicine</i> , <b>2006</b> , 7, 1-9	2.7	14
220	Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Medicine, 2006, 7, 16-	<b>24</b> 7	20
219	The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. <i>HIV Medicine</i> , <b>2006</b> , 7, 218-30	2.7	245
218	Nutritional status and prognosis in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 563-72	6.1	127
217	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , <b>2006</b> , 440, 1217-21	50.4	525
216	Twenty five years of HIV infection in haemophilic men in Britain: an observational study. <i>BMJ, The</i> , <b>2005</b> , 331, 997-8	5.9	4
215	Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 910-7	6.9	30
214	Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. <i>Aids</i> , <b>2005</b> , 19, 1627-33	3.5	47
213	Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. <i>Aids</i> , <b>2005</b> , 19, 85-90	3.5	126
212	Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. <i>Aids</i> , <b>2005</b> , 19, 487-94	3.5	98
211	The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 416-23		103
210	An unusual form of autoimmune hepatitis in young Somalian men. <i>Liver International</i> , <b>2005</b> , 25, 325-30	7.9	33
209	Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 519-24	6.1	29
208	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. <i>Liver Transplantation</i> , <b>2005</b> , 11, 386-95	4.5	85
207	Sociodemography of genital co-infection with Neisseria gonorrhoeae and Chlamydia trachomatis in Coventry, UK. <i>International Journal of STD and AIDS</i> , <b>2005</b> , 16, 318-22	1.4	3

206	Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. Journal of Infectious Diseases, <b>2005</b> , 192, 967-73	7	56
205	Higher vaginal pH is associated with Chlamydia trachomatis infection in women: a prospective case-controlled study. <i>International Journal of STD and AIDS</i> , <b>2005</b> , 16, 290-3	1.4	13
204	The attitude of patients towards medical students in a sexual health clinic. <i>Sexually Transmitted Infections</i> , <b>2005</b> , 81, 437-9	2.8	17
203	Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. <i>BMJ, The</i> , <b>2005</b> , 330, 695	5.9	62
202	Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1509-15	0.7	188
201	Newly diagnosed HIV infections: review in UK and Ireland. <i>BMJ, The</i> , <b>2005</b> , 330, 1301-2	5.9	108
200	The epidemiology of genital infection with herpes simplex virus types 1 and 2 in genitourinary medicine attendees in inner London. <i>Sexually Transmitted Infections</i> , <b>2005</b> , 81, 306-8	2.8	6
199	Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. <i>Circulation Research</i> , <b>2005</b> , 97, e97-103	15.7	105
198	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 8309-14	11.5	172
197	Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1772-82	11.6	180
196	The rate of viral rebound after attainment of an HIV load . <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 138	87 <del>7</del> 97	35
195	Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. <i>BMJ, The</i> , <b>2005</b> , 331, 1368	5.9	139
194	No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). <i>Aids</i> , <b>2005</b> , 19, 513-20	3.5	92
193	Predictors of hypertension and changes of blood pressure in HIV-infected patients. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 811-23	1.6	42
192	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 459-467	1.6	10
191	Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1056-74	7	284
190	South Asians with HIV in London: is it time to rethink sexual health service delivery to meet the needs of heterosexual ethnic minorities?. <i>Sexually Transmitted Infections</i> , <b>2004</b> , 80, 75-6	2.8	3
189	Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1860-8	7	110

188	Pitfalls of assessing hepatotoxicity in trials and observational cohorts. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38 Suppl 2, S56-64	11.6	16
187	The impact of HIV on mortality rates in the complete UK haemophilia population. <i>Aids</i> , <b>2004</b> , 18, 525-33	3.5	38
186	Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. <i>Aids</i> , <b>2004</b> , 18, 2145-51	3.5	168
185	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. <i>Immunology</i> , <b>2004</b> , 112, 255-64	7.8	60
184	Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. <i>HIV Medicine</i> , <b>2004</b> , 5, 88-92	2.7	37
183	Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. <i>HIV Medicine</i> , <b>2004</b> , 5, 314-314	2.7	1
182	von Willebrand disease in women with menorrhagia: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2004</b> , 111, 734-40	3.7	167
181	Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2004</b> , 24, 1214-8	7.3	118
180	The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response. <i>Journal of Medical Virology</i> , <b>2004</b> , 72, 187-93	19.7	5
179	A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1355-61	7	76
178	Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. <i>Lancet, The,</i> <b>2004</b> , 363, 2116-21	40	148
177	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , <b>2004</b> , 364, 51-62	40	267
176	HIV/HCV coinfection, HAART, and liver-related mortality. <i>Lancet, The</i> , <b>2004</b> , 364, 757-8; author reply 758	<b>3</b> 40	12
175	Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 37, 1155-9	3.1	21
174	Cardio- and cerebrovascular events in HIV-infected persons. <i>Aids</i> , <b>2004</b> , 18, 1811-7	3.5	181
173	The Problems Faced When Assessing the Prevalence and Incidence of Antiretroviral-Related Toxicities. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 865-878	1.6	1
172	Cardiovascular disease risk factors in HIV patients lassociation with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , <b>2003</b> , 17, 1179-1193	3.5	645
171	Combination antiretroviral therapy and the risk of myocardial infarction. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1993-2003	59.2	1336

170	Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. <i>Aids</i> , <b>2003</b> , 17, 1009-16	3.5	4
169	Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. <i>Aids</i> , <b>2003</b> , 17, 2665-7	3.5	15
168	The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 963-9	3.5	59
167	Immunological changes during treatment interruptions. <i>Aids</i> , <b>2003</b> , 17, 126-128	3.5	12
166	Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2003</b> , 32, 303-10	3.1	19
165	Definition of loss of virological response in trials of antiretroviral drugs. <i>Aids</i> , <b>2003</b> , 17, 1997-8	3.5	6
164	Findings from the first national clinical audit of treatment for people with HIV. HIV Medicine, <b>2003</b> , 4, 11-7	2.7	26
163	Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. <i>HIV Medicine</i> , <b>2003</b> , 4, 1-10	2.7	74
162	An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. <i>HIV Medicine</i> , <b>2003</b> , 4, 87-93	2.7	31
161	Pre-travel preparation and outcome of HIV-infected travellers from a UK clinic. <i>Travel Medicine and Infectious Disease</i> , <b>2003</b> , 1, 114-8	8.4	6
160	Differences in presentation and follow-up between HIV-1 antibody positive teenagers and adults: the need for a more focused approach to care?. <i>Aids</i> , <b>2003</b> , 17, 260-2	3.5	4
159	Viral breakthrough after suppression with highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 768-770	3.5	5
158	Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , <b>2003</b> , 17, 1179-93	3.5	312
157	Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 301-8	1.6	
156	Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 301-308	1.6	
155	Impact of the insect biting nuisance on a British youth expedition to Alaska. <i>Journal of Travel Medicine</i> , <b>2002</b> , 9, 76-81	12.9	5
154	Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders. <i>Journal of Medical Virology</i> , <b>2002</b> , 68, 68-75	19.7	4
153	DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. <i>Haemophilia</i> , <b>2002</b> , 8, 787-93	3.3	59

# (2001-2002)

152	The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 470-6	7	10
151	Human immunodeficiency virus rebound after suppression to . <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1086-91	7	42
150	The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. <i>Aids</i> , <b>2002</b> , 16 Suppl 4, S61-8	3.5	35
149	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 951-8	7.8	54
148	Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186 Suppl 1, S110-5	7	40
147	Chlamydial co-infection among patients with gonorrhoea. <i>International Journal of STD and AIDS</i> , <b>2002</b> , 13, 261-3	1.4	18
146	Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 197-202	3.1	56
145	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. <i>Aids</i> , <b>2002</b> , 16, 53-61	3.5	80
144	The changing pattern of bronchoscopy in an HIV-infected population. <i>Chest</i> , <b>2002</b> , 122, 878-85	5.3	9
143	Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. <i>Aids</i> , <b>2002</b> , 16, 2129-35	3.5	22
142	A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. <i>Gastroenterology</i> , <b>2002</b> , 123, 1013-9	13.3	178
141	Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. <i>Pharmacoeconomics</i> , <b>2002</b> , 20, 759-74	4.4	54
140	Early assessment of anti-HIV drug efficacy. Lancet, The, 2002, 359, 1696-7; author reply 1697	40	
139	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , <b>2002</b> , 360, 119-29	40	1246
138	Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. <i>Lancet, The</i> , <b>2002</b> , 360, 1546-51	40	30
137	Highly active antiretroviral therapy and cervical intraepithelial neoplasia. <i>Aids</i> , <b>2002</b> , 16, 927-9	3.5	26
136	CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. <i>Aids</i> , <b>2002</b> , 16, 1073-5	3.5	17
135	Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 26, 462-5	3.1	8

134	Long-Term Follow-Up of Antiretroviral-Naive HIV-Positive Patients Treated With Nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 462-465	3.1	12
133	Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Medicine, 2001, 2, 52-8	2.7	35
132	Assessing the relationship between productivity levels and severity of haemophilia. <i>Haemophilia</i> , <b>2001</b> , 7, 459-63	3.3	2
131	The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1518-21	7	18
130	Cohort studies in sexual health. Sexually Transmitted Infections, 2001, 77, 174-8	2.8	3
129	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. <i>Aids</i> , <b>2001</b> , 15, 185-94	3.5	150
128	Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2001</b> , 47, 371-5	5.1	14
127	Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 511-4	7	6
126	Blood and graft eosinophils in acute cellular rejection of liver allografts. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 2588-93	1.1	19
125	Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. <i>Aids</i> , <b>2001</b> , 15, 2379-84	3.5	36
124	The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. <i>Aids</i> , <b>2001</b> , 15, 47-54	3.5	37
123	Health-related quality of life in individuals infected with HIV in the era of HAART. <i>HIV Clinical Trials</i> , <b>2001</b> , 2, 484-92		58
122	Reduced bone mineral density in HIV-positive individuals. <i>Aids</i> , <b>2001</b> , 15, 1731-3	3.5	94
121	Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. <i>Aids</i> , <b>2001</b> , 15, 2051-3	3.5	26
120	A study of the incidence of accidents occurring during an Arctic expedition: another important aspect of travel medicine?. <i>Journal of Travel Medicine</i> , <b>2000</b> , 7, 205-7	12.9	10
119	A survey of the profile and perceived value of a London Travel Clinic. <i>Journal of Travel Medicine</i> , <b>2000</b> , 7, 330-2	12.9	1
118	The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. <i>Aids</i> , <b>2000</b> , 14, 2129-36	3.5	33
117	Course of viral load throughout HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2000</b> , 23, 172-7	3.1	40

# (2000-2000)

116	The role of observational studies in assessing the impact of antiviral therapies. <i>Current Opinion in Infectious Diseases</i> , <b>2000</b> , 13, 631-635	5.4	2	
115	The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. <i>HIV Clinical Trials</i> , <b>2000</b> , 1, 27-35		11	
114	A practical guide to applying the intention-to-treat principle to clinical trials in HIV infection. <i>HIV Clinical Trials</i> , <b>2000</b> , 1, 31-8		10	
113	The inhibition of cutaneous T cell apoptosis may prevent resolution of inflammation in atopic eczema. <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 122, 150-6	6.2	19	
112	Reproductive choices of women in families with haemophilia. <i>Haemophilia</i> , <b>2000</b> , 6, 33-40	3.3	39	
111	Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?. <i>Journal of Internal Medicine</i> , <b>2000</b> , 247, 493-9	10.8	27	
110	The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 136-142	4.5	2	
109	Detection of antibodies to human herpesvirus 8 in Italian children: evidence for horizontal transmission. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 702-4	8.7	61	
108	Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. <i>Aids</i> , <b>2000</b> , 14, 1829-37	3.5	23	
107	Course of Viral Load Throughout HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2000</b> , 23, 172-177	3.1	42	
106	Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. <i>Aids</i> , <b>2000</b> , 14, 1001-7	3.5	18	
105	Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. <i>Aids</i> , <b>2000</b> , 14, 1163-70	3.5	75	
104	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. <i>Aids</i> , <b>2000</b> , 14, 2857-67	3.5	161	
103	Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. <i>AIDS Research and Human Retroviruses</i> , <b>2000</b> , 16, 1025-30	1.6	38	
102	The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. <i>Gut</i> , <b>2000</b> , 47, 845-51	19.2	135	
101	Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1804-7	7	11	
100	Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 1610-5	7	21	
99	Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1800-3	7	20	

98	Resistance profiles in patients with viral rebound on potent antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1143-7	7	27
97	Viral-load kinetics and CMV disease. <i>Lancet, The</i> , <b>2000</b> , 356, 1353	40	
96	Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. <i>Lancet, The</i> , <b>2000</b> , 355, 2032-6	40	427
95	The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 136-42	4.5	15
94	Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. <i>Transplantation</i> , <b>2000</b> , 69, 2400-4	1.8	104
93	Variations in Coagulation Factors in Women: Effects of Age, Ethnicity, Menstrual Cycle and Combined Oral Contraceptive. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 1456-1461	7	130
92	Observing the process of care: a stroke unit, elderly care unit and general medical ward compared. <i>Age and Ageing</i> , <b>1999</b> , 28, 433-40	3	23
91	Assessing the impact of highly active antiretroviral therapy on AIDS and death. <i>Aids</i> , <b>1999</b> , 13, 2165-6	3.5	5
90	Family issues in HIV-infected haemophilic patients. <i>Aids</i> , <b>1999</b> , 13, 2314-5	3.5	1
89	Changes in AIDS-Defining Illnesses in a London Clinic, 1987¶998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1999</b> , 21, 401		15
88	Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 179, 234-6	7	67
87	Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. <i>Gut</i> , <b>1999</b> , 44, 264-9	19.2	70
86	Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis	7	42
85	Study Group. Journal of Infectious Diseases, 1999, 180, 695-701  CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. Journal of Infectious Diseases, 1999, 180, 530-3	7	64
84	Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Journal of Infectious Diseases, <b>1999</b> , 180, 600-6	7	106
83	Assessing health-related quality-of-life in patients with severe haemophilia A and B. <i>Psychology, Health and Medicine</i> , <b>1999</b> , 4, 5-15	2.1	25
82	Serum soluble transferrin receptor in the diagnosis of iron deficiency in chronic liver disease. <i>International Journal of Laboratory Hematology</i> , <b>1999</b> , 21, 93-7		8
81	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. <i>HIV Medicine</i> , <b>1999</b> , 1, 32-9	2.7	9

80	Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. <i>Haemophilia</i> , <b>1999</b> , 5, 40-8	3.3	126
79	Assessing health-related quality-of-life in individuals with haemophilia. <i>Haemophilia</i> , <b>1999</b> , 5, 378-85	3.3	150
78	Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG) <b>1999</b> , 58, 182-187		47
77	Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. Journal of Medical Virology, <b>1999</b> , 58, 280-5	19.7	11
76	The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination. <i>Vaccine</i> , <b>1999</b> , 17, 1329-37	4.1	19
75	Risk of new AIDS diseases in people on triple therapy. <i>Lancet, The</i> , <b>1999</b> , 353, 463	40	32
74	Neural tube defects and periconceptional folic acid in England and Wales: retrospective study. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 92-3		43
73	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. <i>Aids</i> , <b>1999</b> , 13, 1255-61	3.5	41
72	Virological response to protease inhibitor therapy in an HIV clinic cohort. <i>Aids</i> , <b>1999</b> , 13, 367-73	3.5	90
71	Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. <i>Aids</i> , <b>1999</b> , 13, 951-6	3.5	94
7°	Changes in AIDS-Defining Illnesses in a London Clinic, 1987¶998. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 21, 401	3.1	36
69	Impact of KaposiN sarcoma on HIV disease progression. <i>Aids</i> , <b>1999</b> , 13, 286	3.5	2
68	Pregnancy in women with von WillebrandN disease or factor XI deficiency. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1998</b> , 105, 314-21	3.7	211
67	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von WillebrandN disease. <i>Journal of Internal Medicine</i> , <b>1998</b> , 244, 515-5	22 <sup>0.8</sup>	67
66	Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. <i>Bone Marrow Transplantation</i> , <b>1998</b> , 21, 597-605	4.4	138
65	Cofactors and markers of disease progression in human immunodeficiency virus infection. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>1998</b> , 161, 177-189	2.1	5
64	Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. <i>Hepatology</i> , <b>1998</b> , 27, 1207-12	11.2	338
63	Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. <i>Journal of Medical Virology</i> , <b>1998</b> , 56, 316-20	19.7	11

62	The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. <i>Haemophilia</i> , <b>1998</b> , 4, 4-9	3.3	19
61	Quality of life during menstruation in patients with inherited bleeding disorders. <i>Haemophilia</i> , <b>1998</b> , 4, 836-41	3.3	97
60	Frequency of inherited bleeding disorders in women with menorrhagia. <i>Lancet, The</i> , <b>1998</b> , 351, 485-9	40	387
59	The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. <i>Journal</i>	7	38
58	Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with Journal of Infectious Diseases, <b>1998</b> , 178, 1166-9	7	1
57	HIV follow-up care at a London teaching hospital. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>1998</b> , 10, 165-73	2.2	
56	Hepatitis C virus and HIV coinfection. AIDS Patient Care and STDs, 1998, 12, 199-207	5.8	3
55	Outcome of orthotopic liver transplantation in patients with haemophilia. <i>Gut</i> , <b>1998</b> , 42, 744-9	19.2	121
54	Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1998</b> , 19, 546-8		19
53	Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion Study. <i>Aids</i> , <b>1998</b> , 12, 1353-60	3.5	2
52	Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. <i>Aids</i> , <b>1998</b> , 12, 1347-52	3.5	25
51	Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. <i>Aids</i> , <b>1998</b> , 12, 605-11	3.5	40
50	A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. <i>Aids</i> , <b>1998</b> , 12, 1155-61	3.5	10
49	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. <i>Epidemiology and Infection</i> , <b>1998</b> , 121, 369-76	4.3	12
48	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand disease 1998, 244, 515		3
47	Alpha-glutathione-S-transferase in acute rejection of liver transplant recipients. <i>Transplantation</i> , <b>1998</b> , 65, 401-5	1.8	13
46	The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. <i>Journal of Immunology</i> , <b>1998</b> , 161, 1619-29	5.3	59
45	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand disease. <i>Journal of Internal Medicine</i> , <b>1998</b> , 244, 515-23	2 10.8	9

### [1996-1997]

44	Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 176, 1484-90	7	169
43	The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 164-8	7	144
42	Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 775-80	7	20
41	Orthopaedic Surgery in Hemophilic Patients With Human Immunodefiency Virus. <i>Clinical Orthopaedics and Related Research</i> , <b>1997</b> , 343, 81???87	2.2	21
40	Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. <i>Aids</i> , <b>1997</b> , 11, 889-93	3.5	106
39	The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. <i>Epidemiology and Infection</i> , <b>1997</b> , 118, 259-66	4.3	10
38	Survival after a very low (Aids, <b>1997</b> , 11, 1123-7	3.5	3
37	Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. <i>Pharmacoeconomics</i> , <b>1997</b> , 12, 54-66	4.4	54
36	Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. <i>Tissue Antigens</i> , <b>1997</b> , 50, 8-14		95
35	Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation <b>1997</b> , 52, 200-205		53
34	Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. <i>BMJ: British Medical Journal</i> , <b>1997</b> , 314, 329-33		90
33	Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. <i>BMJ: British Medical Journal</i> , <b>1997</b> , 314, 409-13		43
32	Cross-sectional studies in AIDS pathogenesis: how far can they mislead us?. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 14, 153-7		1
31	CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 14, 158-62		89
30	Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 16, 279-8	3	3
29	Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation <b>1997</b> , 52, 200		5
28	Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. <i>Aids</i> , <b>1996</b> , 10, 827-34	3.5	135
27	Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. <i>Aids</i> , <b>1996</b> , 10, 344-5	3.5	69

26	Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. <i>Aids</i> , <b>1996</b> , 10, 1515-20	3.5	74
25	The use of intermediate-purity clotting factor concentrates and HIV disease progression in men with haemophilia. <i>Haemophilia</i> , <b>1996</b> , 2, 78-81	3.3	1
24	Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A. <i>BMJ: British Medical Journal</i> , <b>1996</b> , 312, 207-10		6
23	Response: arguments contradict the "foreign protein-zidovudine" hypothesis. <i>BMJ: British Medical Journal</i> , <b>1996</b> , 312, 211-2		1
22	Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 13, 262-6		8
21	Prophylaxis for Pneumocystis carinii pneumonia: its impact on the natural history of HIV infection in men with haemophilia. <i>Haemophilia</i> , <b>1995</b> , 1, 37-44	3.3	2
20	HIV results in the frame. Antiviral therapy. <i>Nature</i> , <b>1995</b> , 375, 195; author reply 198	50.4	20
19	Morbidity and mortality from transfusion-transmitted disease in haemophilia. <i>Lancet, The</i> , <b>1995</b> , 345, 1309	40	11
18	Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. <i>Lancet, The</i> , <b>1995</b> , 346, 12-7	40	42
17	Hospital costs of treating haemophilic patients infected with HIV. Aids, 1995, 9, 787-93	3.5	15
16	The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. <i>Epidemiology and Infection</i> , <b>1995</b> , 114, 361-72	4.3	52
15	Viral burden in HIV infection. <i>Nature</i> , <b>1994</b> , 367, 124	50.4	7
14	Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care. <i>British Journal of Haematology</i> , <b>1994</b> , 86, 366-71	4.5	14
13	The progression of HCV-associated liver disease in a cohort of haemophilic patients. <i>British Journal of Haematology</i> , <b>1994</b> , 87, 555-61	4.5	241
12	A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. <i>Vaccine</i> , <b>1994</b> , 12, 978-83	4.1	4
11	The Use of Backcalculation to Estimate the Prevalence of Severe Immunodeficiency Induced by Human Immunodeficiency Virus in England and Wales. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>1994</b> , 157, 41	2.1	2
10	Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection. <i>BMJ: British Medical Journal</i> , <b>1994</b> , 309, 309-13		51
9	CD4+ Counts before and after Switching to Monoclonal High-Purity Factor VIII Concentrate in HIV-Infected Haemophilic Patients. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 72, 214-217	7	15

#### LIST OF PUBLICATIONS

8	Are there two types of response to HIV?. Lancet, The, 1993, 341, 1023-4	40	1	
7	New AIDS definition. <i>Lancet, The</i> , <b>1993</b> , 341, 178	40		
6	CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. <i>Aids</i> , <b>1993</b> , 7, 975-80	3.5	45	
5	Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. <i>American Journal of Epidemiology</i> , <b>1993</b> , 138, 870-8	3.8	30	
4	The progression of HIV disease in a haemophilic cohort followed for 12 years. <i>British Journal of Haematology</i> , <b>1993</b> , 83, 330-3	4.5	25	
3	Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. <i>Clinical and Experimental Immunology</i> , <b>1992</b> , 88, 243-52	6.2	157	
2	Immunodeficiency and the risk of death in HIV infection. <i>JAMA - Journal of the American Medical Association</i> , <b>1992</b> , 268, 2662-6	27.4	12	
1	Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study		7	